Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Teva
Dow
US Department of Justice
Novartis
Cantor Fitzgerald
Argus Health
Farmers Insurance
AstraZeneca
Fish and Richardson

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,370,879

« Back to Dashboard

Summary for Patent: 5,370,879
Title: Formulations and their use in the treatment of neurological diseases
Abstract:Pharmaceutical formulations comprise a mono- or di-aminopyridine active agent for administration on a once- or twice-daily basis for use in the treatment of neurological diseases, in particular multiple sclerosis and Alzheimer's disease. The formulations, which are suitable for oral or percutaneous administration of the active agent, include the active agent in a carrier effective to permit release of the mono- or di-aminopyridine at a rate allowing controlled absorption thereof over, on the average, not less than a 12 hour period and at a rate sufficient to achieve therapeutically effective blood levels over a period of 12-24 hours following administration.
Inventor(s): Masterson; Joseph G. (London, GB), Myers; Michael (Athlone, IE)
Assignee: Elan Corporation, plc (Athlone, IE)
Application Number:08/073,651
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Device;

Drugs Protected by US Patent 5,370,879

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,370,879

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Ireland3952/90Feb 11, 1990

International Patents Family Members for US Patent 5,370,879

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 188118 ➤ Sign Up
Australia 657706 ➤ Sign Up
Australia 8696191 ➤ Sign Up
Canada 2054822 ➤ Sign Up
Czechoslovakia 9103313 ➤ Sign Up
Germany 122011100057 ➤ Sign Up
Germany 69131880 ➤ Sign Up
Denmark 0484186 ➤ Sign Up
European Patent Office 0484186 ➤ Sign Up C300503 Netherlands ➤ Sign Up
European Patent Office 0484186 ➤ Sign Up 91894 Luxembourg ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Argus Health
McKinsey
Express Scripts
Colorcon
Queensland Health
Farmers Insurance
US Army
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot